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The tremendous progress made over the past decade in
understanding the molecular basis of various heritable skin
disorders has clearly made an impact by providing refined,
molecularly based classifications, improved prognostica-
tion, and premises for prenatal diagnosis (Uitto et al, 2002).
There has, however, been relatively little impact on treat-
ment of these conditions. One of the areas under active
development of treatment modalities for genodermatoses is
gene therapy, a potentially powerful way of correcting the
consequences of mutations in these conditions at the ge-
netic level.
In principle, there are two broad approaches to gene
therapy—ex vivo and in vivo. Ex vivo gene therapy primarily
revolves around the use of cultured cells, such as keratin-
ocytes, obtained from the affected individuals; these cells
are propagated and transduced in culture to re-express the
gene that is defective in the patients. In the case of kera-
tinocytes, the transgenic cells can be grown to form epi-
thelial sheets and incorporated into a skin explant that can
be regrafted to the donor. The overall goal of the keratin-
ocyte gene transfer is efficient targeting of stem cell pop-
ulations allowing sustained expression of the transgene,
and the desired end point of this approach is synthesis and
assembly of the wild-type protein and its supramolecular
organization to correct the deficiency in the diseased skin.
This approach can also accommodate the use of specific
promoters for stable, tissue-specific, and modulatable ex-
pression of the transgene.
In vivo gene therapy uses the introduction of the trans-
gene directly into the target tissue. This can be approached
by either direct injection of the genetic material into the skin
or mucous membranes, utilizing biolistic particle bombard-
ment (‘‘gene gun’’), or topical application mediated by
physico-chemical means, including liposomes, in vivo
electroporation, etc. (Lin et al, 2000; Hengge and Barden-
heyer, 2004). The premise of this approach is that DNA is
taken up by the resident cells in the skin, and the transgene
then becomes expressed through coupled transcription/
translation. In either approach, the strategic considerations
should take into account replacement versus repair of the
defective gene; selection of the delivery systems (viral vs
physical/chemical); and, importantly, preclinical testing for
safety and efficacy in animal models of the human disease.
A number of model systems have been proposed as
targets for development of gene therapy for genoder-
matoses (Table I). The choice largely depends on the type
of mutations, mode of inheritance, and consequences of the
genetic lesions at the mRNA and protein levels. For exam-
ple, transgenic animals, such as those generated by ho-
mozygous ablation of the gene in mice, often recapitulate
the features of autosomal recessive human diseases, and
can serve as suitable animal models for gene therapy. Sim-
ilarly, expression of mutated genes that cause dominant-
negative interference and result in dominantly inherited dis-
ease serve as appropriate models for some conditions. Ex
vivo skin explants and cell cultures established from pa-
tients with the disease, and by extension, grafting of human
skin from patients into immunocompromised mice, can also
serve the purpose of being a target for gene therapy de-
velopment. Finally, a number of naturally occurring muta-
tions in a variety of animal species have been disclosed in a
manner that they mimic the human disease.
The prototype of conditions demonstrating significant
progress in molecular genetics is epidermolysis bullosa
(EB), a group of heritable mechanobullous disorders (Uitto
and Richard, 2004). Specific molecular defects have been
identified in ten distinct genes expressed at the cutaneous
basement membrane zone, and the majority of mutations
are single-base pair substitutions or small insertions or de-
letions that may be amenable to gene therapy approaches.
Consequently, EB has been considered an excellent can-
didate disease for gene correction strategies (Uitto and
Pulkkinen, 2000).
Table I. Model systems as target for development of gene
therapy for genodermatoses
Naturally occurring mutations in animal species
Transgenic knockout mice
Expression of mutated genes with dominant-negative interference
Human skin/equivalent grafted into immunocompromised mice
Ex vivo skin explants/cell cultures
Abbreviation: EB, epidermolysis bullosa
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A number of transgenic animal models have been de-
veloped to mimic the clinical features of EB. For example, a
number of ‘‘knockout’’ animals have been generated by
targeted ablation of the candidate genes, such as those
encoding type VII collagen (COL7A1) or the subunit poly-
peptides of laminin 5 (LAMA3, LAMB3, and LAMC2), as
models of dystrophic and junctional forms of EB, respec-
tively (Table II). In addition, a number of naturally occurring
animal diseases mimicking EB have been disclosed (Table
II). In early reports, the type of EB was not defined, and only





mutationw Clinical/genetic featuresz Reference
Simplex
EBS Mouse KRT14 T Basal cell cytolysis with keratin aggregates Vassar et al (1991)
EBS Mouse KRT14 T Focal, inducible activation of the mutant KRT14
allele
Cao et al (2001)
EBS Bovine ? N Suprabasilar clefts at stratum spinosum Agerholm (1994)
EBS Bovine ? N Simmental X Red Holstein calf with suprabasilar
clefts
Stocker et al (1995)
Hemidesmosomal
EB-PA Mouse ITGA6 T Targeted ablation of the gene results in severe
blistering at birth; lethal in day 1
Georges-Labouesse
et al (1996)
EB-PA Mouse ITGB4 T Similar to ITGA6 knockout mouse van der Neut et al
(1996)
EB-PA Mouse ITGB4 T Targeted deletion of the b4 integrin cytoplasmic
domain; lethal at birth
Murgia et al (1998)
EB-MD Mouse PLEC1 T Neonatal blistering with late-onset muscular
dystrophy
Andra et al (1997)
GABEB Dog COL17A1 (?) N Defective expression of type XVII collagen; non-
lethal phenotype
Olivry et al (1997)
Junctional
H-JEB Mouse LAMA3 T Targeted disruption of the gene; neonatal lethal Ryan et al (1999)
H-JEB Mouse LAMC2 T Targeted ablation of exon 8; neonatal lethal Meng et al (2003)
H-JEB Mouse LAMB3 N Spontaneous, intragenic insertion of an
intracisternal-A particle
Kuster et al (1997)
H-JEB Dog ? N Subepidermal blisters; LL separation with laminin
and collagen IV at the base
Dunstan et al (1988)
H-JEB Horse ? N LL tissue separation Frame et al (1988)
NH-JEB Dog ? N LL blistering; expression of laminin 5 positive Nagata et al (1997)
H-JEB Horse LAMC2 N Homozygous 1368insC in Belgian horse; severe
blistering and exungulation
Spirito et al (2002)




NH-JEB Dog LAMA3 N Homozygous 4818þ207ins6.5 kb of repetitive
satellite DNA within exon 35; mild phenotype
Capt et al, 2005
(this issue)
Dystrophic
RDEB Mouse COL7A1 T Targeted ablation of exons 46–69; severe blistering
at birth
Heinonen et al (1999)
RDEB Sheep COL7A1 N Alpine sheep with early blisters and exungulation;





Dog COL7A1 (?) N Reduced number of anchoring fibrils; LH7.2 staining
positive; mild clinical features
Nagata et al (1995)
DEB Cat COL7A1 N Reduced AF formation; subepidermal clefting below
the lamina densa
Olivry et al (1999)
RDEB Dog COL7A1 N Mutation G1906S; autosomal recessive inheritance Baldeschi et al (2003)
EBS, epidermolysis bullosa simplex; GABEB, generalized atrophic benign EB; EB-PA, EB with pyloric atresia; EB-MD, EB with muscular dystrophy;
H-JEB, Herlitz junctional EB; NH-JEB, non-Herlitz JEB; RDEB, recessive dystrophic EB (for clinical features of these EB variants in humans, see Uitto
and Richard, 2004); wT, Transgenic animal; N, naturally occurring mutations; zLL, lamina lucida; AF, anchoring fibrils.
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recently have specific mutations in the genes of these an-
imals been delineated.
In this issue, Capt et al (2005) describe an animal model,
a German pointer, with junctional EB. Specifically, this par-
ticular dog breed harbors a homozygous insertion mutation
within the LAMA3 gene encoding the a3 subunit polypep-
tide of laminin 5. But, since the insertion is within an intron
(no. 35) of this gene, some synthesis of the wild-type a3
chain of laminin is observed, resulting in a low level of ex-
pression of immunodetectable laminin 5. Consequently, the
clinical phenotype is relatively mild, consistent with non-
Herlitz junctional EB. Thus, this dog breed appears to pro-
vide a suitable model for preclinical exploration of thera-
peutics for EB.
Collectively, the availability of animal models for hu-
man genodermatoses, as highlighted here by EB, provides
a basis for gene therapy approaches for the treatment of
these currently intractable, often devastating, diseases.
DOI: 10.1111/j.0022-202X.2005.23652.x
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